{"id":2953,"date":"2016-10-24T19:17:31","date_gmt":"2016-10-24T23:17:31","guid":{"rendered":"https:\/\/www.med.unc.edu\/genetics\/directory\/mark-heise-phd\/"},"modified":"2025-04-15T14:02:48","modified_gmt":"2025-04-15T18:02:48","slug":"mark-heise-phd","status":"publish","type":"directory","link":"https:\/\/www.med.unc.edu\/genetics\/directory\/mark-heise-phd\/","title":{"rendered":"Mark Heise, PhD"},"content":{"rendered":"

<\/p>\n

Research Interests<\/h2>\n

Keywords: Viral pathogenesis, virus-host interactions, genetics of virulence, vaccine development, antiviral drug development<\/strong><\/p>\n

Lab Website<\/a><\/strong><\/p>\n

The Heise Lab uses a combination of molecular virology, viral immunology, and systems genetics approaches to study the pathogenesis of mosquito-borne and respiratory viruses.\u00a0 These viruses include chikungunya virus (CHIKV), a mosquito-borne alphavirus that causes severe arthralgia in humans, influenza A virus (IAV), a significant seasonal and pandemic threat to human health, and SARS-CoV2.\u00a0 Our CHIKV studies are focused on the identification of viral and host factors that contribute to the pathogenesis of CHIKV-induced tenosynovitis, and understanding how interactions among these factors affect disease outcomes.\u00a0 We are also part of a large interdisciplinary Systems Genetics program at UNC, where work in our lab is focused on the identification and characterization of polymorphic host genes that contribute to variation in the host immune responses following IAV, CHIKV, or SARS-CoV2 infection, as well as vaccination.\u00a0 In addition to gaining new insights into the pathogenesis of several significant human pathogens, our goal is to leverage this research to develop new vaccines or therapies for the prevention or treatment of these important human pathogens.\u00a0 As part of this effort, Dr. Heise is a founding member, along with Drs. Ralph Baric and Nathaniel Moorman, of the Rapidly Emerging Antiviral Drug Development Initiative (READDI<\/strong>), a consortium focused on the development of broad spectrum antiviral drugs designed to head off future pandemics.<\/p>\n

Alphavirus Molecular Pathogenesis:<\/strong>\u00a0 We have developed a number of molecular clones and other reagent for analyzing CHIKV virulence determinants, and we are using these tools in combination with mouse models of CHIKV-induced tenosynovitis to study how specific viral genetic elements affect the pathogenesis of CHIKV-induced disease.\u00a0 We are also collaborating with several labs at UNC to identify novel RNA secondary structures within the genomes of CHIKV and other alphaviruses, and then test whether these RNA structural elements affect viral replication or disease pathogenesis.<\/p>\n

Systems Genetics of Viral Infection or Vaccine Response:<\/strong>\u00a0 Host genetic variation plays a major role in determining how individuals respond to infection or vaccination, yet our understanding of these processes is incomplete.\u00a0 Therefore, we are using the Collaborative Cross (CC), a highly diverse mouse genetic reference population designed to model human genetic diversity, to study how host genetic variation affects susceptibility to viral infection or shapes the immune response following virus challenge or vaccination.\u00a0 These studies are focused on: 1) testing the impact of genetic variation on immune homeostasis, 2) mapping polymorphic genes that contribute to variation in IAV, CHIKV, or SARS-CoV2 infection, as well as vaccine-induced innate or adaptive immunity, 3) understanding how genetic variation affects the host response to different vaccine adjuvants, and 4) the identification of polymorphic genes that control susceptibility to acute CHIKV-induced joint disease.<\/p>\n

Alphavirus Therapeutics:<\/strong> CHIKV and other alphaviruses are significant emerging disease threats, however there are currently no approved antivirals for treating alphavirus-induced disease.\u00a0 Therefore, we are using our alphavirus molecular biology expertise and mouse models of alphavirus-induced disease to test candidate antiviral molecules for their therapeutic efficacy against CHIKV and other emerging alphaviruses.<\/p>\n

Coronavirus Vaccines and Therapeutics:\u00a0 <\/strong>We are working with academic and industry partners to develop and test new, broad spectrum antiviral therapies for treating SARS-CoV2 and other emerging coronaviruses.\u00a0 These efforts include projects evaluating both host targeted and direct acting antivirals, as well as studies evaluating the safety and efficacy of anti-inflammatory drugs for treating SARS-CoV2-induced pulmonary disease.\u00a0 We are also using mouse models of SARS-CoV2 pathogenesis to test the safety and efficacy of novel coronavirus vaccine platforms.\u00a0 These studies include efforts to identify host pathways that mediate protection against SARS-CoV2-induced disease, as well as the identification of host factors that contribute to vaccine-failure. \u00a0<\/strong><\/p>\n

Mentor Training:<\/h2>\n